The Food and Drug Administration (FDA) announced on Monday the appointment of George Tidmarsh, a former executive from the biotechnology industry, as its new chief drug regulator. Tidmarsh, who also holds a position as an adjunct professor of pediatrics and neonatal science at Stanford University School of Medicine, will oversee one of the FDA's largest and most crucial departments, tasked with reviewing marketing applications for the vast majority of new drugs.